Cargando…
Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease
In a slowly progressive disorder like Alzheimer disease, evaluation of the clinical effect of novel drug candidates requires large numbers of patients and extended treatment periods. Current cell- and animal-based disease models of Alzheimer disease are poor at predicting a positive treatment respon...
| Autores principales: | , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3031878/ https://www.ncbi.nlm.nih.gov/pubmed/21122172 http://dx.doi.org/10.1186/alzrt56 |